Stay updated on Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial page.

Latest updates to the Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe clinical trial record for rucaparib and nivolumab is displayed, with study details, participation criteria, treatment plan, outcomes, record dates, and a linked protocol document. The record states that the study was terminated due to lack of efficacy and is no longer recruiting.SummaryDifference58%

- Check17 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide NIH notice appears above the ClinicalTrials.gov navigation, announcing a website transition and changes in terminology around artificial intelligence.SummaryDifference1%

- Check31 days agoChange DetectedThe site footer revision changed from v3.7.1 to v3.7.2 while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer site revision changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check52 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the expected study record content and showing only the site header and footer.SummaryDifference0.5%

Stay in the know with updates to Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial page.